These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 8170171)

  • 1. Comparison of the intracellular pharmacokinetics of daunorubicin and idarubicin in patients with acute leukemia.
    Tidefelt U; Sundman-Engberg B; Paul C
    Leuk Res; 1994 Apr; 18(4):293-7. PubMed ID: 8170171
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative pharmacokinetic study of idarubicin and daunorubicin in leukemia patients.
    Robert J; Rigal-Huguet F; Hurteloup P
    Hematol Oncol; 1992; 10(2):111-6. PubMed ID: 1592361
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and cerebrospinal fluid penetration of daunorubicin, idarubicin, and their metabolites in the nonhuman primate model.
    Berg SL; Reid J; Godwin K; Murry DJ; Poplack DG; Balis FM; Ames MM
    J Pediatr Hematol Oncol; 1999; 21(1):26-30. PubMed ID: 10029808
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of idarubicin and daunorubicin and their main metabolites regarding intracellular uptake and effect on sensitive and multidrug-resistant HL60 cells.
    Tidefelt U; Prenkert M; Paul C
    Cancer Chemother Pharmacol; 1996; 38(5):476-80. PubMed ID: 8765443
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of idarubicin after oral administration in elderly leukemic patients.
    Robert J; Rigal-Huguet F; Huet S; Pris J; Hurteloup P
    Leukemia; 1990 Mar; 4(3):227-9. PubMed ID: 2179640
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma pharmacokinetics and cerebrospinal fluid concentrations of idarubicin and idarubicinol in pediatric leukemia patients: a Childrens Cancer Study Group report.
    Reid JM; Pendergrass TW; Krailo MD; Hammond GD; Ames MM
    Cancer Res; 1990 Oct; 50(20):6525-8. PubMed ID: 2208112
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma pharmacokinetics of idarubicin and its 13-dihydro metabolite--a comparison of bolus versus 2 h infusion during a 3 day course.
    Eksborg S; Björkholm M; Hast R; Fagerlund E
    Anticancer Drugs; 1997 Jan; 8(1):42-7. PubMed ID: 9147610
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cellular uptake and antiproliferative effects of therapeutic concentrations of idarubicin or daunorubicin and their alcohol metabolites, with or without cyclosporin A, in MDR1+ human leukemic cells.
    Chiodini B; Bassan R; Barbui T
    Leuk Lymphoma; 1999 May; 33(5-6):485-97. PubMed ID: 10342576
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Flow cytometric study of idarubicin and daunorubicin accumulation and the effect of verapamil in leukemic cell lines and fresh cells from patients with acute non-lymphoblastic leukemia.
    Boiron JM; Belloc F; Montastruc M; Cony-Makhoul P; Dumain P; Marit G; Mahon FX; Puntous M; Lopez F; Lacombe F
    Leuk Res; 1994 May; 18(5):313-8. PubMed ID: 8182921
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of idarubicin after daily intravenous administration in leukemic patients.
    Robert J; Rigal-Huguet F; Harousseau JL; Pris J; Huet S; Reiffers J; Hurteloup P; Tamassia V
    Leuk Res; 1987; 11(11):961-4. PubMed ID: 3480399
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral idarubicin pharmacokinetics--correlation of trough level with idarubicin area under curve.
    Schleyer E; Kühn S; Rührs H; Unterhalt M; Kaufmann CC; Kern W; Braess J; Sträubel G; Hiddemann W
    Leukemia; 1997 Dec; 11 Suppl 5():S15-21. PubMed ID: 9436933
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro effect of multidrug resistance modifiers on idarubicinol efflux in blasts of acute myeloid leukemia.
    Schröder JK; Kasimir-Bauer S; Seeber S; Scheulen ME
    J Cancer Res Clin Oncol; 2000 Feb; 126(2):111-6. PubMed ID: 10664252
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral idarubicin pharmacokinetics--correlation of trough level with idarubicin area under curve.
    Schleyer E; Kühn S; Rührs H; Unterhalt M; Kaufmann CC; Kern W; Braess J; Sträubel G; Hiddemann W
    Leukemia; 1996 Apr; 10(4):707-12. PubMed ID: 8618451
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cyclosporin increases cellular idarubicin and idarubicinol concentrations in relapsed or refractory AML mainly due to reduced systemic clearance.
    Smeets M; Raymakers R; Muus P; Vierwinden G; Linssen P; Masereeuw R; de Witte T
    Leukemia; 2001 Jan; 15(1):80-8. PubMed ID: 11243404
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and tissue distribution of idarubicin and its active metabolite idarubicinol in the rabbit.
    Looby M; Linke R; Weiss M
    Cancer Chemother Pharmacol; 1997; 39(6):554-6. PubMed ID: 9118470
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of daunorubicin and doxorubicin in plasma and leukemic cells from patients with acute nonlymphoblastic leukemia.
    Paul C; Liliemark J; Tidefelt U; Gahrton G; Peterson C
    Ther Drug Monit; 1989; 11(2):140-8. PubMed ID: 2718219
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The influence of intracellular idarubicin and daunorubicin levels on drug cytotoxicity in childhood acute leukemia.
    Styczyński J; Wysocki M; Debski R; Kurylak A; Balwierz W; Rokicka-Milewska R; Matysiak M; Balcerska A; Kowalczyk J; Wachowiak J; Sońta-Jakimczyk D; Chybicka A
    Acta Biochim Pol; 2002; 49(1):99-107. PubMed ID: 12136962
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase I study of idarubicin hydrochloride in patients with acute leukemia. The Idarubicin Study Group of Japan.
    Tamura K
    Semin Hematol; 1996 Oct; 33(4 Suppl 3):2-11. PubMed ID: 8916310
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I clinical trial of orally administered 4-demethoxydaunorubicin (idarubicin) with pharmacokinetic and in vitro drug sensitivity testing in children with refractory leukemia.
    Pui CH; de Graaf SS; Dow LW; Rodman JH; Evans WE; Alpert BS; Murphy SB
    Cancer Res; 1988 Sep; 48(18):5348-52. PubMed ID: 3165708
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of oral idarubicin in breast cancer patients with reference to antitumor activity and side effects.
    Elbaek K; Ebbehøj E; Jakobsen A; Juul P; Rasmussen SN; Bastholt L; Dalmark M; Steiness E
    Clin Pharmacol Ther; 1989 Jun; 45(6):627-34. PubMed ID: 2731405
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.